No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
XCUR Exicure
- 0.3240
- +0.0138+4.45%
Trading Jul 3 09:46 ET
2.80MMarket Cap-214P/E (TTM)
0.3240High0.3150Low623Volume0.3100Open0.3102Pre Close199.05Turnover0.01%Turnover RatioLossP/E (Static)8.65MShares1.470052wk High1.27P/B2.53MFloat Cap0.300052wk Low--Dividend TTM7.81MShs Float115.2000Historical High--Div YieldTTM2.90%Amplitude0.3000Historical Low0.3190Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Exicure | 10-Q: Quarterly report
Exicure GAAP EPS of -$0.10, Revenue of $0.5M
Express News | Exicure Q1 EPS $(0.10) Up From $(0.70) YoY, Sales $500.00K
Express News | Exicure Inc - Substantial Additional Financing Needed in Very Near Term to Pay Expenses, Fund Ongoing Exploration of Strategic Alternatives
Express News | Exicure Inc -Qtrly Shr Loss $0.10
Express News | Exicure Inc - Has Already Engaged in Significant Cost Reductions, so Our Ability to Further Cut Costs and Extend Company's Operating Runway Is Limited
Comments
$Exicure(XCUR.US$ Exicure Shares Are Trading Lower After the Company Reported FY23 Results and Said It Believes That Its Cash and Cash Equivalents Are Insufficient to Continue to Fund Operations and Additional Funding Is Needed in the Very Near Term
1
$Exicure(XCUR.US$ small float👀
2
1
$Exicure(XCUR.US$ Will go higher
$Exicure(XCUR.US$ EXICURE XCUR PATENT AGREEMENT WITH BLUEJAY; HELIUS HSDT FDA FEEDBACK
BPC UPDATE 02/06/2024 ET
Pre-Market Updates
Exicure Inc (NASDAQ: XCUR) announced that it has licensed some of its patents to Bluejay Thearapeutics for advanced clinical development on the treatment of hepatitis. Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of the deal.![]()
BPC UPDATE 02/06/2024 ET
Pre-Market Updates
Exicure Inc (NASDAQ: XCUR) announced that it has licensed some of its patents to Bluejay Thearapeutics for advanced clinical development on the treatment of hepatitis. Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of the deal.
1
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg